Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trialH. Miles Prince, M. D’Incan, Erin Zagadailov et al.|The Lancet|2017Cited by 580
CD4+ T cell-induced inflammatory cell death controls immune-evasive tumoursBastian Kruse, Thomas Tüting, Anthony Buzzai et al.|Nature|2023Cited by 296
A cellular hierarchy in melanoma uncouples growth and metastasisPanagiotis Karras, Jean‐Christophe Marine, Ignacio Bordeu et al.|Nature|2022Cited by 249
A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanomaJoanna Poźniak, Jean‐Christophe Marine, Dennis Pedri et al.|Cell|2024Cited by 175
Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanomaOskar Marín-Béjar, Jean‐Christophe Marine, Aljosja Rogiers et al.|Cancer Cell|2021Cited by 154